Skip to Content

Nymalize Side Effects

Generic Name: nimodipine

Note: This page contains side effects data for the generic drug nimodipine. It is possible that some of the dosage forms included below may not apply to the brand name Nymalize.

For the Consumer

Applies to nimodipine: oral capsule liquid filled, oral solution, oral tablet

As well as its needed effects, nimodipine (the active ingredient contained in Nymalize) may cause unwanted side effects that require medical attention.

Major Side Effects

If any of the following side effects occur while taking nimodipine, check with your doctor immediately:

Less common:
  • Blurred vision
  • chest pain or discomfort
  • confusion
  • difficult or labored breathing
  • fast, pounding, or irregular heartbeat or pulse
  • lightheadedness, dizziness, or fainting
  • shortness of breath
  • slow or irregular heartbeat
  • sweating
  • swelling
  • tightness in the chest
  • unusual tiredness or weakness

Minor Side Effects

Some nimodipine side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

Less common:
  • Abdominal or stomach cramps, discomfort, or pain
  • back pain
  • blemishes on the skin
  • constipation
  • diarrhea
  • discouragement
  • feeling sad or empty
  • headache
  • indigestion
  • irritability
  • lack or loss of appetite
  • loss of interest or pleasure
  • muscle pain
  • nausea or vomiting
  • pimples
  • rash
  • swollen mouth and tongue
  • tiredness
  • trouble concentrating
  • trouble sleeping
  • unpleasant taste
  • urge to have bowel movement

For Healthcare Professionals

Applies to nimodipine: oral capsule, oral liquid


Cardiovascular effects have frequently been associated with the use of nimodipine (the active ingredient contained in Nymalize) and are related to its vasodilatory properties. Mild to moderate hypotension has been reported in up to 5% of patients, and was the reason less than 1% of patients chose to discontinue therapy. Bradycardia has been reported and may be severe in rare cases. Rare cardiovascular side effects have included tachycardia, hypertension, peripheral edema, dizziness, and flushing. A case of pulmonary vasoconstriction has been associated with the use of this drug.[Ref]

Nervous system

The incidence of nervous system side effects associated with the use of nimodipine (the active ingredient contained in Nymalize) has been similar to placebo in large studies. Headache has been reported in 4% of patients, and is believed to be due to the vasodilatory properties of nimodipine.[Ref]


Hepatic effects include transient, reversible elevations in liver function tests.[Ref]


Hematologic side effects are rare and have included thrombocytopenia and anemia.[Ref]


Gastrointestinal intolerance occurs occasionally.[Ref]


Dermatologic effects include occasional cases of rash.[Ref]


1. Grobe-Einsler R "Clinical aspects of nimodipine." Clin Neuropharmacol 16 (1993): S39-45

2. "Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Trust Study Group." Lancet 336 (1990): 1205-9

3. Jan M, Buchheit F, Tremoulet M "Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms." Neurosurgery 23 (1988): 154-7

4. Lovell AT, Smith M "Pulmonary vasoconstriction following intravenous nimodipine." Anaesthesia 47 (1992): 409-10

5. Sramek JJ, Heller AH, Sundaresan PR, Lettieri J, Sawin S, Cutler NR "Safety and tolerance of intravenous nimodipine." Ann Pharmacother 28 (1994): 1143-8

6. Fagan SC, Nacci N "Nimodipine and bradycardia in acute stroke--drug or disease?" DICP 25 (1991): 247-9

7. Langley MS, Sorkin EM "Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease." Drugs 37 (1989): 669-99

8. "Product Information. Nimotop (nimodipine)." Bayer, West Haven, CT.

9. Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, Disney LB, Khan MI, Grace M, Holness RO, et al "Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial." J Neurosurg 68 (1988): 505-17

10. Florence G, Bonvento G, Roucher P, Charbonne R, Seylaz J "Effect of nimodipine on the autoregulation of cerebral blood flow studied by laser-doppler flowmetry." Brain Res 625 (1993): 301-6

11. Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJ "A controlled trial of nimodipine in acute ischemic stroke." N Engl J Med 318 (1988): 203-7

12. Torrealba G, Sharp A, Soto B "Nimodipine-treated subarachnoid hemorrhage associated with acute pseudo-obstruction of the colon." Surg Neurol 28 (1987): 150-2

It is possible that some side effects of Nymalize may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.